JP2017516802A - がんの治療におけるエリブリンの使用 - Google Patents

がんの治療におけるエリブリンの使用 Download PDF

Info

Publication number
JP2017516802A
JP2017516802A JP2016569857A JP2016569857A JP2017516802A JP 2017516802 A JP2017516802 A JP 2017516802A JP 2016569857 A JP2016569857 A JP 2016569857A JP 2016569857 A JP2016569857 A JP 2016569857A JP 2017516802 A JP2017516802 A JP 2017516802A
Authority
JP
Japan
Prior art keywords
eribulin
agent
breast cancer
administered
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016569857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516802A5 (enExample
Inventor
ブルース， エー． リトルフィールド，
ブルース， エー． リトルフィールド，
マコト アサノ，
マコト アサノ，
ジュンジ マツイ，
ジュンジ マツイ，
マーティン オリヴォ，
マーティン オリヴォ，
ヨウイチ オザワ，
ヨウイチ オザワ，
ヤンケ ユー，
ヤンケ ユー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2017516802A publication Critical patent/JP2017516802A/ja
Publication of JP2017516802A5 publication Critical patent/JP2017516802A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016569857A 2014-05-28 2015-05-27 がんの治療におけるエリブリンの使用 Pending JP2017516802A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462003937P 2014-05-28 2014-05-28
US62/003,937 2014-05-28
PCT/US2015/032684 WO2015183961A1 (en) 2014-05-28 2015-05-27 Use of eribulin in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2017516802A true JP2017516802A (ja) 2017-06-22
JP2017516802A5 JP2017516802A5 (enExample) 2018-08-30

Family

ID=54699716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016569857A Pending JP2017516802A (ja) 2014-05-28 2015-05-27 がんの治療におけるエリブリンの使用

Country Status (13)

Country Link
US (1) US20170100367A1 (enExample)
EP (1) EP3148526B1 (enExample)
JP (1) JP2017516802A (enExample)
KR (1) KR20170039096A (enExample)
CN (1) CN106413705A (enExample)
AU (1) AU2015267099B2 (enExample)
BR (1) BR112016026545A8 (enExample)
CA (1) CA2950320A1 (enExample)
IL (2) IL249220B (enExample)
MX (1) MX2016015378A (enExample)
RU (1) RU2699545C2 (enExample)
SG (1) SG11201609777SA (enExample)
WO (1) WO2015183961A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023525321A (ja) * 2020-05-11 2023-06-15 ヨンスン ファイン ケミカル カンパニー，リミテッド 結晶性エリブリン塩

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005250487B2 (en) 2004-06-03 2012-03-29 Eisai R&D Management Co., Ltd Intermediates for the preparation of analogs of halichondrin B
AU2010232347A1 (en) 2009-03-30 2011-09-29 Eisai R&D Management Co., Ltd. Liposome composition
AU2014299699B2 (en) 2013-06-26 2019-10-10 Eisai R&D Management Co., Ltd. Use of eribulin and lenvatinib as combination therapy for treatment of cancer
KR20170122810A (ko) 2015-03-04 2017-11-06 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 에리불린의 조합
EP3449921B1 (en) 2016-04-28 2023-05-31 Eisai R&D Management Co., Ltd. Eribulin for inhibiting tumor growth
MA47502A (fr) * 2017-02-20 2019-12-25 Polyphor Ag Combinaisons pharmaceutiques pour traiter le cancer
WO2019017497A1 (en) * 2017-07-21 2019-01-24 Eisai R&D Management Co., Ltd. USE OF CYCLIN-DEPENDENT KINASE ERIBULINE AND INHIBITORS IN THE TREATMENT OF CANCER
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
JP2022506829A (ja) * 2018-11-09 2022-01-17 ジー１、セラピューティクス、インコーポレイテッド エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
US20060104984A1 (en) * 1998-06-17 2006-05-18 Littlefield Bruce A Methods and compositions for use in treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2755266C (en) 1998-06-17 2014-08-12 Eisai R&D Management Co., Ltd. Intermediates for preparing macrocyclic analogs
AU2005250487B2 (en) 2004-06-03 2012-03-29 Eisai R&D Management Co., Ltd Intermediates for the preparation of analogs of halichondrin B
EP2200992B1 (en) 2007-10-03 2014-02-26 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin b analogs
BR112012018232B8 (pt) 2010-01-26 2023-01-10 Eisai R&D Man Co Ltd Compostos derivados de furo [3,2-b] pirano úteis na síntese de análogos de halicondrina b e métodos de sintetização de er-80402 e de eribulina
SG193489A1 (en) * 2011-03-18 2013-10-30 Eisai R&D Man Co Ltd Methods and compositions for predicting response to eribulin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
US20060104984A1 (en) * 1998-06-17 2006-05-18 Littlefield Bruce A Methods and compositions for use in treating cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Eribulin in combination with capecitabine for adjuvant treatment in estrogen receptor-positive early", NCTO1439282 ON 2014_02_07: CLINICALTRIAIS.GOV ARCHIVE, JPN6019025224, 7 February 2014 (2014-02-07), ISSN: 0004360622 *
BIODRUGS, vol. 27, JPN6019025225, 2013, pages 469 - 478, ISSN: 0004360623 *
JW SMITH ET AL: "Eribulin mesylate (Erib) plus capecitabine (X) for adjuvant treatment in post-menopausal estrogen re", JOURNAL OF CLINICAL ONCOLOGY, vol. 31(15 supp), JPN6019025223, 2013, ISSN: 0004360621 *
NCTO1795586 ON 2014_01_22: CLINICALTRIAIS.GOV ARCHIVE, JPN6019025227, 2014, ISSN: 0004069088 *
岡山医学会雑誌, vol. 119, JPN6019025226, 2008, pages 319 - 322, ISSN: 0004069087 *
日本臨床（増刊）, vol. 70(7), JPN6020037874, 2012, pages 763 - 772, ISSN: 0004360624 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023525321A (ja) * 2020-05-11 2023-06-15 ヨンスン ファイン ケミカル カンパニー，リミテッド 結晶性エリブリン塩
JP7465584B2 (ja) 2020-05-11 2024-04-11 ヨンスン ファイン ケミカル カンパニー，リミテッド 結晶性エリブリン塩
US12486283B2 (en) 2020-05-11 2025-12-02 Yonsung Fine Chemical Co., Ltd. Crystalline salt of eribulin

Also Published As

Publication number Publication date
SG11201609777SA (en) 2016-12-29
AU2015267099A1 (en) 2017-01-05
IL249220B (en) 2020-08-31
EP3148526A4 (en) 2018-03-14
CN106413705A (zh) 2017-02-15
US20170100367A1 (en) 2017-04-13
WO2015183961A1 (en) 2015-12-03
MX2016015378A (es) 2017-12-04
AU2015267099A8 (en) 2020-08-27
CA2950320A1 (en) 2015-12-03
IL249220A0 (en) 2017-02-28
BR112016026545A8 (pt) 2021-07-06
EP3148526A1 (en) 2017-04-05
KR20170039096A (ko) 2017-04-10
BR112016026545A2 (pt) 2017-08-15
EP3148526B1 (en) 2021-01-06
RU2016151303A3 (enExample) 2019-01-17
RU2699545C2 (ru) 2019-09-06
IL276733A (en) 2020-09-30
RU2016151303A (ru) 2018-07-02
AU2015267099B2 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
JP2017516802A (ja) がんの治療におけるエリブリンの使用
JP6648040B2 (ja) がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用
KR102265952B1 (ko) 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도
US20170071903A1 (en) Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer
CN111902147A (zh) 五氮杂大环状环配合物和基于铂的抗癌剂的组合癌症治疗
KR20210005714A (ko) 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법
KR20210008527A (ko) 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물 및 이의 사용 방법
US9937261B2 (en) Combination therapy comprising a liposomal prodrug of mitomycin C and radiotherapy
KR20210010524A (ko) 샘낭암종을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물
WO2021102404A1 (en) Lung targeted anticancer therapies with liposomal annamycin
JP6644479B2 (ja) がん治療のための併用療法としてのエリブリンとｓ−１（もしくは５−ｆｕ）の使用
JP2008540566A (ja) ２−デオキシグルコースを用いたがんの処置
US20220071982A1 (en) Methods and uses for treating cancer
CN120569198A (zh) 一种内磺酰胺化合物治疗胆道癌的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200423

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201006